Literature DB >> 29308301

Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.

Megan C Duggan1, Amanda R Campbell1,2, Elizabeth L McMichael1, Kallan S Opheim1, Kala M Levine1, Neela Bhave1, Michelle C Culbertson1, Tiffany Noel1, Lianbo Yu3, W E Carson1,4.   

Abstract

Natural killer (NK) cells serve a critical role in the immune response against microbes and developing tumors. We have demonstrated that NK cells produce stimulatory cytokines (e.g., IFN-γ) in response to potent stimulation via immobilized IgG (to engage Fc receptors) and interleukin (IL)-12. CD25 is a component of the high-affinity IL-2R, which promotes NK cell activation in response to low doses of IL-2 such as those released by activated T cells. We hypothesized that stimulation of NK cells via IgG and IL-12 would enhance CD25 expression and promote NK cell anti-tumor activity in response to low-dose IL-2. It was confirmed that this dual stimulation strategy significantly enhanced NK cell CD25 expression compared to unstimulated cells or cells treated with IgG or IL-12 alone. Dual stimulated NK cells also were more responsive to low-dose IL-2. Dual stimulated NK cells subsequently treated with low-dose IL-2 (10 pg/mL) displayed enhanced intracellular signaling as indicated by increased pSTAT5 levels. IFN-γ production and cytotoxicity against K562 cells by NK cells stimulated with low-dose IL-2 was comparable to that of cells treated with high-dose IL-2 (10 ng/mL). Importantly, cells isolated from head and neck cancer patients receiving the mAb cetuximab and IL-12 on a clinical trial displayed increased CD25 expression following combination therapy compared to baseline. Altogether, these findings suggest that FcR and IL-12R co-stimulation induces expression of the high-affinity IL-2R and promotes NK cell anti-tumor activity.

Entities:  

Keywords:  CD25; interleukin 12; interleukin 2; natural killer cells

Year:  2017        PMID: 29308301      PMCID: PMC5749624          DOI: 10.1080/2162402X.2017.1381813

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  47 in total

1.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

Authors:  Todd A Fehniger; Megan A Cooper; Gerard J Nuovo; Marina Cella; Fabio Facchetti; Marco Colonna; Michael A Caligiuri
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 2.  Mechanisms of NK cell activation: CD4(+) T cells enter the scene.

Authors:  Franck Bihl; Claire Germain; Carmelo Luci; Veronique M Braud
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

Review 3.  NKG2D Receptor and Its Ligands in Host Defense.

Authors:  Lewis L Lanier
Journal:  Cancer Immunol Res       Date:  2015-06       Impact factor: 11.151

4.  CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells.

Authors:  Maria-Elena Márquez; Carmen Millet; Hilda Stekman; Angela Conesa; Pierre-Antoine Deglesne; Felix Toro; Juan De Sanctis; Isaac Blanca
Journal:  Cell Immunol       Date:  2010-05-10       Impact factor: 4.868

5.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

6.  A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

Authors:  Tanios S Bekaii-Saab; Julie M Roda; Kristan D Guenterberg; Bhuvanaswari Ramaswamy; Donn C Young; Amy K Ferketich; Tammy A Lamb; Michael R Grever; Charles L Shapiro; William E Carson
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

7.  The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Authors:  Julie M Roda; Trupti Joshi; Jonathan P Butchar; Jaclyn W McAlees; Amy Lehman; Susheela Tridandapani; William E Carson
Journal:  Clin Cancer Res       Date:  2007-10-25       Impact factor: 12.531

Review 8.  Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

Authors:  M A Caligiuri
Journal:  Semin Oncol       Date:  1993-12       Impact factor: 4.929

9.  Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection.

Authors:  Brian Badgwell; Robin Parihar; Cynthia Magro; Julie Dierksheide; Thomas Russo; William Edgar Carson
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

Review 10.  The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma.

Authors:  Laura A Pachella; Lydia T Madsen; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2015-05-01
View more
  7 in total

Review 1.  From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement.

Authors:  Loïs Coënon; Martin Villalba
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

2.  Activating natural killer (NK) cytotoxicity of canine CD5-CD21- cells requires low surface CD5 density NK cells.

Authors:  C S Lin; C P Chang; H C Chiang; T F Chuang; C H Hsu; C C Liu
Journal:  Iran J Vet Res       Date:  2018       Impact factor: 1.376

Review 3.  Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors.

Authors:  Jens H W Pahl; Adelheid Cerwenka; Jing Ni
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

Review 4.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

Authors:  Isaure Vanmeerbeek; Jenny Sprooten; Dirk De Ruysscher; Sabine Tejpar; Peter Vandenberghe; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2020-01-09       Impact factor: 8.110

Review 5.  The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.

Authors:  Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; Jorrit De Waele; An Wouters
Journal:  Front Immunol       Date:  2021-09-07       Impact factor: 7.561

Review 6.  Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.

Authors:  Chaopin Yang; Yue Li; Yaozhang Yang; Zhiyi Chen
Journal:  J Immunol Res       Date:  2020-01-21       Impact factor: 4.818

7.  Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.

Authors:  Roberta Sommaggio; Elisa Cappuzzello; Anna Dalla Pietà; Anna Tosi; Pierangela Palmerini; Debora Carpanese; Lorenzo Nicolè; Antonio Rosato
Journal:  Oncoimmunology       Date:  2020-06-11       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.